Abstract
The purpose of the study was to evaluate and compare the incidence and dynamics of drug resistance of M.tuberculosis to antituberculosis drugs in the Belgorod and Voronezh regions in different categories of patients: newly diagnosed, relapse, and other cases of repeated treatment. A comparative analysis of the spectral incidence and dynamics of M. tuberculosis drug resistance in 2007 and 2016 in the Belgorod and Voronezh regions was carried out. The data of statistical accounting forms 07-TB and centralized bacteriological laboratories were used. When comparing the data of the two regions - the Belgorod and Voronezh regions - both general trends and significant differences in the levels and dynamics of drug resistance of M. tuberculosis have been identified in different categories of patients. The level of primary multiple drug resistance is higher in the Voronezh Region, its growth rates in the Belgorod Region are the same, and the growth in overall sustainability is twice higher than in the Voronezh Region. It should be noted that the proportion of mono-resistant to isoniazid strains in the Belgorod region is increasing, while in Voronezh this phenomenon does not exist. The issues of epidemiological monitoring of tuberculosis require increased attention and detailed analysis at the territorial level for the adoption of adequate and effective management decisions. The current system of routine epidemic monitoring requires improvement taking into account the Russian and international experience. Data of such monitoring can have a significant impact on management decision-making in the field of tuberculosis control. Including at the level of each region.
Full text article
Generated from XML file
Authors
Oleg А. Zemlyanski, Elena B. Turina, Elena V. Kaliuzhnaya, Galina V. Efron, Luidmila О. Zemlyanskaya, & Natalia N. Shinkarenko. (2023). Comparative characteristics of medical stability m. tuberculosis in Belgorod and Voronezh regions, Russia. International Journal of Research in Pharmaceutical Sciences, 9(3), 626–629. Retrieved from https://ijrps.com/home/article/view/4300
Copyright (c) 2018 International Journal of Research in Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.